The asymmetrictransferhydrogenation (ATH) of a wide range of ketones catalyzed by manganese complex as well as chiral PxNy-type ligand under mild conditions was investigated. Using 2-propanol as hydrogen source, various ketones could be enantioselectively hydrogenated by combining cheap, readily available [MnBr(CO)5] with chiral, 22-membered macrocyclic ligand (R,R,R',R')-CyP2N4 (L5) with 2 mol%
研究了锰配合物以及手性P x N y型配体在温和条件下催化的多种酮的不对称转移氢化(ATH)。使用2-丙醇作为氢源,可以通过将廉价的,易于获得的[MnBr(CO)5 ]与手性22元大环配体(R,R,R ',R ')-CyP 2 N结合起来,对映异构地氢化各种酮4(L5)具有2 mol%的催化剂负载量,可提供具有高达95%ee的高度有价值的手性醇。
Ruthenium-catalyzed hydrogenation of aromatic ketones using chiral diamine and monodentate achiral phosphine ligands
作者:Mengna Wang、Ling Zhang、Hao Sun、Qian Chen、Jian Jiang、Linlin Li、Lin Zhang、Li Li、Chun Li
DOI:10.1016/j.catcom.2021.106303
日期:2021.6
The Ru-catalyzed asymmetric hydrogenation of ketones with chiral diamine and monodentate achiral phosphine has been developed. A wide range of ketones were hydrogenated to afford the corresponding chiral secondary alcohols in good to excellent enantioselectivities (up to 98.1% ee). In addition, an appropriate mechanism for the asymmetric hydrogenation was proposed and verified by NMR spectroscopy.
propan-2-ol. In the presence of potassium hydroxide, the enantioselective reduction of heteroaromatic ketones proceeded smoothly to give chiral alcohols with excellent enantiomeric excess (up to 97% ee) under mild conditions without reduction of the heterocycle. asymmetric - transfer hydrogenation - catalysis - heteroaromatic ketones - heteroaromatic alcohols
[EN] PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(+)-N,N-DIMETHYL-3-(1-NAPHTHALENYLOXY)-3-(2-THIENYL)PROPANAMINE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE (S)-(+)-N,N-DIMÉTHYL-3-(1-NAPHTALÉNYLOXY)-3-(2-THIÉNYL)PROPANAMINE OPTIQUEMENT ACTIVE
申请人:TEVA PHARMA
公开号:WO2007123900A2
公开(公告)日:2007-11-01
[EN] Duloxetine intermediates, processes for their preparation, and their conversion to pharmaceutically acceptable salts of duloxetine are described. [FR] L'invention concerne des produits intermédiaires de duloxétine, des procédés de préparation de ces produits intermédiaires et leur conversion en sels de duloxétine pharmaceutiquement acceptables.